Cargando…

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation

In allogeneic stem cell mobilization, peripheral blood stem cell mobilization with filgrastim can be considered standard of care. Poor mobilizers may be at risk for inadequate stem cell collection during apheresis. He we present a successful case of salvage plerixafor use with filgrastim in a haploi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadeau, Michelle, George, Laeth, Yeager, Andrew M, Anwer, Faiz, McBride, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574786/ https://www.ncbi.nlm.nih.gov/pubmed/26401275 http://dx.doi.org/10.1002/ccr3.327

Ejemplares similares

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2020)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2021)

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
por: Awan, Farrukh T., et al.
Publicado: (2012)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts
por: Rutella, Sergio, et al.
Publicado: (2014)

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study
por: de Greef, Georgine E., et al.
Publicado: (2018)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges
por: Ashruf, Omer S, et al.
Publicado: (2023)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Strategies in Haploidentical Stem Cell Transplantation in Adults
por: Bayraktar, Ulaş D., et al.
Publicado: (2013)

Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study
por: Tsukada, Nobuhiro, et al.
Publicado: (2021)

Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Jongheon, et al.
Publicado: (2021)

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
por: Cytryn, Samuel, et al.
Publicado: (2020)

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
por: Parody, Rocío, et al.
Publicado: (2020)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
por: Avramova, Boryana E, et al.
Publicado: (2011)

Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation
por: Elmariah, Hany, et al.
Publicado: (2021)

Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies
por: Bi, Xia, et al.
Publicado: (2022)

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation
por: Dybko, Jarosław, et al.
Publicado: (2023)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
por: Moreb, Jan S., et al.
Publicado: (2011)

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Dou, Li-Ping, et al.
Publicado: (2018)

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
por: Visram, Alissa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ne9nikvu7fihddrvr0injm5v11